Venclexta, when combined with azacitidine, elicited an overall survival benefit below 10% in patients with myelodysplastic ...

Venclexta fails to meet survival goals in ABBV's phase III MDS study, marking another clinical setback for the cancer drug.

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

AbbVie said on Monday its treatment for a group of blood cancers failed to meet the main goal of significantly improving the ...

The VERONA study tested the combination of Venclexta and azacitidine against azacitidine plus placebo. Results showed a hazard ratio (HR) of 0.908, indicating that AbbVie’s combination therapy ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), and AbbVie announced today the outcome from the Phase ...

Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...